DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas

被引：1
|
作者：
Gambardella, Valentina
Greystoke, Alastair
Reck, Martin
Liu, Meiruo
Mueller, Martha
Duenzinger, Ulrich
Bergsland, Emily B.
Owonikoko, Taofeek
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT279
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT279
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial
    Tan, Daryl
    Phipps, Colin
    Hwang, William Y. K.
    Tan, Soo Yong
    Yeap, Chun Hsien
    Chan, Yiong Huak
    Tay, Kevin
    Lim, Soon Thye
    Lee, Yuh Shan
    Kumar, Sathish Gopalakrishnan
    Ng, Soo Chin
    Fadilah, S.
    Kim, Won Seog
    Goh, Yeow Tee
    LANCET HAEMATOLOGY, 2015, 2 (08): : E326 - E333
  • [22] Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Viardot, A.
    Goebeler, M.
    Pfreundschuh, M.
    Adrian, N.
    Libicher, M.
    Hess, G.
    Zettl, F.
    Neumann, S.
    Degenhard, E.
    Stieglmaier, J.
    Zhang, A.
    Nagorsen, D.
    Bargou, R. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 33 - 33
  • [23] Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)
    Choudhury, N.
    Jain, P.
    Dowlati, A.
    Thompson, J.
    Johnson, M. L.
    Mamdani, H.
    Sanborn, R. E.
    Schenk, E. L.
    Aggarwal, R.
    Sankar, K.
    Walker, L. N.
    Anand, B.
    Beltran, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S486 - S486
  • [24] Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
    Beltran, Himisha
    Dowlati, Afshin
    Jain, Prantesh
    Johnson, Melissa Lynne
    Sanborn, Rachel E.
    Thompson, Jonathan Robert
    Mamdani, Hirva
    Schenk, Erin L.
    Aggarwal, Rahul Raj
    Sankar, Kamya
    Gramza, Ann W.
    Anand, Banmeet S.
    Choudhury, Noura J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 121 - 121
  • [25] An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
    Izutsu, Koji
    Makita, Shinichi
    Nosaka, Kisato
    Yoshimitsu, Makoto
    Utsunomiya, Atae
    Kusumoto, Shigeru
    Morishima, Satoko
    Tsukasaki, Kunihiro
    Kawamata, Toyotaka
    Ono, Takaaki
    Rai, Shinya
    Katsuya, Hiroo
    Ishikawa, Jun
    Yamada, Hironori
    Kato, Kazunobu
    Tachibana, Masaya
    Kakurai, Yasuyuki
    Adachi, Nobuaki
    Tobinai, Kensei
    Yonekura, Kentaro
    Ishitsuka, Kenji
    BLOOD, 2023, 141 (10) : 1159 - 1168
  • [26] A PHASE 1B, OPEN-LABEL, DOSE-ESCALATION TRIAL OF THE DELTA-LIKE LIGAND 3 (DLL3)/CD3 IGG-LIKE T CELL ENGAGER, BI 764532, IN PATIENTS WITH DLL3-POSITIVE GLIOMA
    van den Bent, Martin
    Roth, Patrick
    Tabatabai, Ghazaleh
    Burger, Michael C.
    Martinez-Garcia, Maria
    von Baumgarten, Louisa
    Greil, Richard
    Studeny, Matus
    Simetzberger, Monika
    Liu, Meiruo
    NEURO-ONCOLOGY, 2023, 25
  • [27] Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).
    Byers, Lauren Averett
    Chiappori, Alberto
    Smit, Marie-Anne Damiette
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial
    Gao, Yan
    Huang, Yunhong
    Zhang, Qingyuan
    Yang, Haiyan
    Li, Yufu
    Li, Yan
    Zhou, Min
    Yang, Runxiang
    Xu, Bing
    Liu, Lihong
    Yang, Yu
    Peng, Zhigang
    Yu, Ding
    Zhou, Hui
    Zhang, Rongyan
    Zhang, Huilai
    Qi, Junyuan
    Xi, Yaming
    Xing, Xiaojing
    Wang, Zhao
    Jing, Hongmei
    Shuang, Yuerong
    Zhang, Xiaohong
    Ma, Liping
    Jin, Hongyan
    Lin, Li'e
    Li, Chunlei
    Xue, Jianfei
    Liu, Yanping
    Yuan, Jing
    Huang, Huiqiang
    CANCER, 2025, 131 (01)
  • [29] Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
    Krebs, Matthew G.
    Delord, Jean-Pierre
    Evans, Thomas R. Jeffry
    De Jonge, Maja
    Kim, Sang-We
    Meurer, Marie
    Postel-Vinay, Sophie
    Lee, Jong-Seok
    Angell, Helen K.
    Rocher-Ros, Vidalba
    Meyer, Kassondra
    Ah-See, Mei-Lin
    Herbolsheimer, Pia
    Lai, Zhongwu
    Nunes, Ana
    Domchek, Susan M.
    LUNG CANCER, 2023, 180
  • [30] An open-label Phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer
    Chu, Quincy
    Gandhi, Leena
    Stephenson, Joe
    Johnson, Bruce E.
    Govindan, Rawasmamy
    Bradford, Daniel
    Bonomi, Phil
    Ellison, David
    Eaton, Keith
    Fritsch, Holger
    Munzert, Gerd
    Socinski, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S811 - S812
12345